… This cell injection regimen is used here to provide the ultimate proof that the trophic actions
of MSCs underlie their cardiovascular therapeutic effects. Using a hamster heart failure …

… When LVEF is >40%, LV mass is increased, and left atrium is enlarged, the diagnosis of
diastolic heart failure needs to be entertained and therapy with angiotensin-converting enzyme (…

… Despite rapidly developing therapy strategies, heart failure has still a poor outcome with
nearly 25% to 50% mortality rate in 5 years after diagnosis. It is often caused by concomitant …

… There is increasing interest in the therapeutic potential of purinergic compounds (including …
The emphasis in this article is on the pathophysiology and therapeutic potential of P2 …

… failure, another disease well known to predispose to coronary artery disease and heart failure,
… In patients with renal failure on hemodialysis, the number and colony-forming capacity of …

… We and others have demonstrated that select PKC isozymes contribute to heart failure (HF).
Isozyme-selective tools that were generated in the past few years, including …

… criteria, recruitment of patients without true heart failure or at early stages of the syndrome,
poor matching of therapeutic mechanisms and primary pathophysiological processes, …

… Treatment of patients with heart failure (HF) and a reduced ejection fraction (HFrEF) is …
reflected in the European Society of Cardiology/Heart Failure Association (ESC/HFA) guidelines, …

… pathophysiology, with the ultimate goal of improving the care of heart failure patients. …
elements of heart failure syndrome and potential contributors to heart failure progression. While …

… necessary evaluation of the therapeutic potential of their EV was, in our view, a crucial step,
necessary for the development of a therapeutic with the potential for widespread clinical use. …